{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:19:34Z","timestamp":1791638374192,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40256-020-00437-7","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T01:02:22Z","timestamp":1600131742000},"page":"255-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels"],"prefix":"10.1007","volume":"21","author":[{"given":"Nathaniel","family":"Eraikhuemen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8176","authenticated-orcid":false,"given":"Dovena","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"issue":"4","key":"437_CR1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"RW Tipping","year":"2009","unstructured":"Tipping RW, Ford CE, Simpson LM, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323.","journal-title":"JAMA"},{"issue":"6","key":"437_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"437_CR3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526\u201337.","journal-title":"J Lipid Res"},{"issue":"6","key":"437_CR4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","volume":"52","author":"S Lamon-Fava","year":"2011","unstructured":"Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52(6):1181\u20137.","journal-title":"J Lipid Res"},{"issue":"7","key":"437_CR5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","volume":"57","author":"B Enkhmaa","year":"2016","unstructured":"Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111\u201325.","journal-title":"J Lipid Res"},{"issue":"1","key":"437_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-016-0024-x","volume":"2","author":"R Saeedi","year":"2016","unstructured":"Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016;2(1):1\u20136. https:\/\/doi.org\/10.1186\/s40842-016-0024-x.","journal-title":"Clin Diabetes Endocrinol."},{"issue":"1","key":"437_CR7","first-page":"76","volume":"103","author":"RC Maranh\u00e3o","year":"2014","unstructured":"Maranh\u00e3o RC, Carvalho PO, Strunz CC, et al. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76\u201384.","journal-title":"Arq Bras Cardiol"},{"issue":"23","key":"437_CR8","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"2","key":"437_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","volume":"125","author":"SS Virani","year":"2012","unstructured":"Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2012;125(2):241\u20139.","journal-title":"Circulation"},{"issue":"10155","key":"437_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0.","journal-title":"Lancet"},{"issue":"27","key":"437_CR11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","volume":"39","author":"R Verbeek","year":"2018","unstructured":"Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589\u201396.","journal-title":"Eur Heart J"},{"issue":"11","key":"437_CR12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","volume":"32","author":"TJ Anderson","year":"2016","unstructured":"Anderson TJ, Gr\u00e9goire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263\u201382.","journal-title":"Can J Cardiol"},{"issue":"7","key":"437_CR13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","volume":"64","author":"MR Langlois","year":"2018","unstructured":"Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol: A consensus statement from EAS and EFLM. Clin Chem. 2018;64(7):1006\u201333.","journal-title":"Clin Chem"},{"key":"437_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000624","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Chair V, et al. Cholesterol clinical practice guidelines: executive summary. Circulation. 2018. https:\/\/doi.org\/10.1161\/CIR.0000000000000624.","journal-title":"Circulation."},{"issue":"3","key":"437_CR15","first-page":"353","volume":"36","author":"G Miltiadous","year":"2006","unstructured":"Miltiadous G, Saougos V, Cariolou M, et al. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Ann Clin Lab Sci. 2006;36(3):353\u20135.","journal-title":"Ann Clin Lab Sci"},{"key":"437_CR16","first-page":"1","volume":"1","author":"S Tsimikas","year":"2019","unstructured":"Tsimikas S, Gordts PLSM, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019;1:1\u201310.","journal-title":"Eur Heart J"},{"key":"437_CR17","doi-asserted-by":"crossref","unstructured":"Yahya R, Berk K, Verhoeven A, et al. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis. 2019; p. 1\u20135.","DOI":"10.1016\/j.atherosclerosis.2019.06.324"},{"issue":"8","key":"437_CR18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","volume":"160","author":"JR Guyton","year":"2000","unstructured":"Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160(8):1177\u201384.","journal-title":"Arch Intern Med"},{"issue":"1","key":"437_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0787-7","volume":"15","author":"A Sahebkar","year":"2017","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Watts GF, et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017;15(1):1\u201314. https:\/\/doi.org\/10.1186\/s12916-017-0787-7.","journal-title":"BMC Med."},{"issue":"459","key":"437_CR20","first-page":"462","volume":"76","author":"W Herrmann","year":"1995","unstructured":"Herrmann W, Biermann J, Kostner GM. Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol. 1995;76(459):462.","journal-title":"Am J Cardiol"},{"issue":"9","key":"437_CR21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/0886022X.2011.605536","volume":"33","author":"A Kooshki","year":"2011","unstructured":"Kooshki A, Taleban FA, Tabibi H, et al. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. Ren Fail. 2011;33(9):892\u20138.","journal-title":"Ren Fail"},{"issue":"2","key":"437_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5551\/jat1994.2.107","volume":"2","author":"K Shinozaki","year":"1996","unstructured":"Shinozaki K, Kambayashi J, Kawasaki T, et al. The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein(a) and lipids in patients with vascular disease. J Atheroscler Thromb. 1996;2(2):107\u20139.","journal-title":"J Atheroscler Thromb."},{"issue":"2","key":"437_CR23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2008.02.004","volume":"2","author":"CM Ballantyne","year":"2008","unstructured":"Ballantyne CM, Davidson MH, McKenney JM, et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80\u00a0mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2(2):79\u201390.","journal-title":"J Clin Lipidol."},{"issue":"10","key":"437_CR24","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","volume":"101","author":"CM Ballantyne","year":"2008","unstructured":"Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non-HDL Cholesterol (from the SEACOAST I Study). Am J Cardiol. 2008;101(10):1428\u201336.","journal-title":"Am J Cardiol"},{"issue":"1","key":"437_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijcard.2011.12.103","volume":"167","author":"F Chen","year":"2013","unstructured":"Chen F, Maccubbin D, Yan L, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin\/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol. 2013;167(1):225\u201331. https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.103.","journal-title":"Int J Cardiol"},{"issue":"2","key":"437_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","volume":"3","author":"W Insull","year":"2009","unstructured":"Insull W, Basile JN, Vo AN, et al. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in\u00a0patients with dyslipidemia: the SUPREME Study. J Clin Lipidol. 2009;3(2):109\u201318. https:\/\/doi.org\/10.1016\/j.jacl.2009.02.009.","journal-title":"J Clin Lipidol."},{"issue":"12","key":"437_CR27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","volume":"62","author":"D Maccubbin","year":"2008","unstructured":"Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959\u201370.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"437_CR28","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","volume":"65","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Reiner \u017d, Simental-Mend\u00eda LE, et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664\u201378.","journal-title":"Metabolism."},{"key":"437_CR29","doi-asserted-by":"crossref","unstructured":"Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8 SUPPL. 1).","DOI":"10.1016\/j.amjcard.2008.02.029"},{"issue":"2","key":"437_CR30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","volume":"52","author":"J Suk Danik","year":"2008","unstructured":"Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52(2):124\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"437_CR31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","volume":"283","author":"MG Shlipak","year":"2000","unstructured":"Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845\u201352.","journal-title":"JAMA"},{"issue":"10","key":"437_CR32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1161\/01.ATV.14.10.1586","volume":"14","author":"DA Shewmon","year":"1994","unstructured":"Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 1994;14(10):1586\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"437_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10557-017-6721-6","volume":"31","author":"G Ferretti","year":"2017","unstructured":"Ferretti G, Bacchetti T, Simental-Mend\u00eda LE, et al. Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Cardiovasc Drugs Ther. 2017;31(2):197\u2013208.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"437_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-019-0792-8","volume":"21","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep. 2019;21(8):1\u20137.","journal-title":"Curr Atheroscler Rep."},{"issue":"3","key":"437_CR35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","volume":"35","author":"RD Santos","year":"2015","unstructured":"Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III Trials. Arterioscler Thromb Vasc Biol. 2015;35(3):689\u201399.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"437_CR36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40256-014-0077-0","volume":"14","author":"N Li","year":"2014","unstructured":"Li N, Li Q, Tian XQ, et al. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2014;14(5):367\u201376.","journal-title":"Am J Cardiovasc Drugs."},{"key":"437_CR37","unstructured":"Tsimikas S. AKCEA-APO(a)-LRx Shows Promise of Reducing Lp(a) Levels in Patients With Preexisting CVD - American College of Cardiology. In: AHA Conference. Chicago, IL. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2018\/11\/07\/15\/19\/sat-445pm-akcea-apo-lrx-to-lower-lipoprotein-aha-2018. Accessed 14 Oct 2019."},{"key":"437_CR38","unstructured":"Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD [NCT04023552]. Available online from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023552. Accessed 2 Sep 2020"},{"issue":"1","key":"437_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/clpt.2011.271\/nature06264","volume":"91","author":"DE Gutstein","year":"2012","unstructured":"Gutstein DE, Krishna R, Johns D, et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012;91(1):109\u201322. https:\/\/doi.org\/10.1038\/clpt.2011.271\/nature06264.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"437_CR40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327.","journal-title":"N Engl J Med"},{"issue":"9992","key":"437_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJP, Van Deventer SJH, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)60158-1.","journal-title":"Lancet"},{"issue":"6","key":"437_CR42","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","volume":"57","author":"FJ Raal","year":"2016","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role. J Lipid Res. 2016;57(6):1086\u201396.","journal-title":"J Lipid Res"},{"issue":"12","key":"437_CR43","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"25","key":"437_CR44","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2012.03.007.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"437_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","volume":"114","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u00a0mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2014.05.060.","journal-title":"Am J Cardiol"},{"issue":"43","key":"437_CR46","first-page":"2996","volume":"36","author":"JJP Kastelein","year":"2015","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH i and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J"},{"issue":"1","key":"437_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","volume":"19","author":"YX Cao","year":"2019","unstructured":"Cao YX, Liu HH, Li S, et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs. 2019;19(1):87\u201397. https:\/\/doi.org\/10.1007\/s40256-018-0303-2.","journal-title":"Am J Cardiovasc Drugs."},{"key":"437_CR48","doi-asserted-by":"crossref","unstructured":"Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12).","DOI":"10.1371\/journal.pone.0014328"},{"issue":"3","key":"437_CR49","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jacl.2017.02.018","volume":"11","author":"C Garc\u00eda-G\u00f3mez","year":"2017","unstructured":"Garc\u00eda-G\u00f3mez C, Mart\u00edn-Mart\u00ednez MA, Casta\u00f1eda S, Sanchez-Alonso F, et al. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol. 2017;11(3):749\u2013756.e3.","journal-title":"J Clin Lipidol."},{"key":"437_CR50","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijcard.2018.06.093","volume":"274","author":"T Ueland","year":"2019","unstructured":"Ueland T, Kleveland O, Michelsen AE, et al. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. Int J Cardiol. 2019;274:348\u201350. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.093.","journal-title":"Int J Cardiol"},{"issue":"9860","key":"437_CR51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyeride transfer protein inhibitor in homozygous familial hypercholesterolemia. Lancet. 2013;381(9860):40\u20136.","journal-title":"Lancet"},{"key":"437_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.phrs.2016.01.030","volume":"105","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Stefanutti C, et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198\u2013209. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.030.","journal-title":"Pharmacol Res"},{"issue":"4","key":"437_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","volume":"78","author":"K Awad","year":"2018","unstructured":"Awad K, Mikhailidis DP, Katsiki N, et al. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled Trials. Drugs. 2018;78(4):453\u201362. https:\/\/doi.org\/10.1007\/s40265-018-0870-1.","journal-title":"Drugs."},{"issue":"8","key":"437_CR54","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","volume":"24","author":"RH Knopp","year":"2003","unstructured":"Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729\u201341.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00437-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T01:43:07Z","timestamp":1631670187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00437-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"15 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nathaniel Eraikhuemen, Dovena Lazaridis, and Matthew T. Dutton have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Conceptualization: [Nathaniel Eraikhuemen]. All authors [Nathaniel Eraikhuemen], [Dovena Lazaridis], and [Matthew T. Dutton] contributed to the the literature search, data analysis, and drafted the originaly work. Critical revisions of the work were performed by [Nathaniel Eraikhuemen] and [Dovena Lazaridis]. All authors performed approval of the final submitted version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}